• Novartis presented positive Phase III REMODEL-1 and REMODEL-2 results for remibrutinib in relapsing multiple sclerosis on October 23, 2026.
• The oral treatment reduced relapses versus teriflunomide, with a clinically meaningful delay in disability progression that reached nominal statistical significance.
• No liver safety signal emerged; treatment discontinuations due to adverse events were lower than with teriflunomide.
• Results were presented at MSToronto2026 and published in The Lancet.
• Global regulatory submissions are planned for remibrutinib in relapsing multiple sclerosis.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Novartis AG published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610231145OMX_____CNEWS_EN_GNW1001279612_en) on October 23, 2026, and is solely responsible for the information contained therein.